Abstract
Parkinson disease (PD) is the second most common neurodegenerative disease; the evidence suggests that lncRNAs and miRNAs play an important role in regulating the PD-related genes. The purpose of this research was to introduce two novel lncRNAs as the biomarker of PD diagnosis and treatment. We evaluated the expression profiles of six nodes of two regulatory networks in the PBMCs which had been got from 38 PD patients and 20 healthy individuals by qRT-PCR. Then, we compared the expression of these RNAs in both early and late stages of PD with the controls to determine if their expression could be related to the severity of disease. Further, this study investigated the direct interaction between one of the lncRNAs and target miRNA by using the dual luciferase assay. The results of the expression profiles of six nodes of the two ceRNA networks shown that linc01128, hsa-miR-24-3p and hsa-miR-30c-5p expression were significantly downregulated. While, the Linc00938, LRRK2 and ATP13A2 expression were up-regulated in the PBMC of the PD patients, in comparison to the controls. In addition, this study demonstrated that linc00938 directly sponged hsa-miR-30c-5p. The present study, therefore, for the first time, revealed two candidate lncRNAs as the biomarkers in the PD patients.
Highlights
Parkinson disease (PD) is the second most common neurodegenerative disease; the evidence suggests that lncRNAs and miRNAs play an important role in regulating the PD-related genes
Non-coding RNAs are risk factors involved in altering the PD-gene expression, playing an important role in PD; several studies have focused on ncRNAs for the diagnosis and treatment of PD, many have not yet been identified
A class of ncRNAs belongs to microRNAs, which are singlestranded RNAs with a length of almost 21–25 nucleotides. miRNAs are small functional ncRNA classes binding to the 3′-untranslated region (UTR) of the target mRNAs; they are suppressing the target gene expression; they are involved in various biological processes[5]
Summary
Parkinson disease (PD) is the second most common neurodegenerative disease; the evidence suggests that lncRNAs and miRNAs play an important role in regulating the PD-related genes. Non-coding RNAs (ncRNAs) are risk factors involved in altering the PD-gene expression, playing an important role in PD; several studies have focused on ncRNAs for the diagnosis and treatment of PD, many have not yet been identified. LncRNAs may function by competing with endogenous RNA (ceRNA) for binding the target miRNA, thereby preventing miRNAs from interacting with mRNAs and altering the gene expression; so, they play roles in various biological processes[6]. Peripheral blood mononuclear cells (PBMCs) are readily available; they are used as a safe source to measure changes in the high quality RNA expression between patients and healthy individuals[7,8] In this regard, many researches have examined the expression profiles related to PD-candidate miRNAs, lncRNAs and mRNAs in PBMCs9,10
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
